Onkos Surgical
- Industry
- Medical Devices
- Founded Year
- 2015
- Headquarters
- 77 East Halsey Road, Parsippany, NJ 07054, USA
- Employee Count
- 113
Key People
- Patrick Treacy - Co-Founder and CEO
- Bradly Tyler - Senior Vice President, Finance and Administration
- Gordon Ballard - Vice President, Operations
- Sean Curry - Chief Commercial Officer
- Chris Wright - Vice President, Sales
- Len Tokish - Vice President, Regulatory and Quality Affairs
Assessment
- Team
-
Aspect: Multiple successful MedTech entrepreneurs
Summary: The leadership team comprises experienced professionals with significant backgrounds in medical technology and business operations.
The presence of multiple successful MedTech entrepreneurs in the leadership team enhances the company's capability to navigate the complex medical device industry, fostering innovation and strategic growth.
- Clinical Need
-
Aspect: Very Strong
Summary: Onkos Surgical addresses significant unmet needs in musculoskeletal oncology and complex orthopedic procedures.
By developing products tailored for complex orthopedic conditions and musculoskeletal oncology, Onkos Surgical fulfills a very strong clinical need, potentially improving patient outcomes and filling gaps in current treatment options.
- Competition
-
Aspect: Somewhat crowded
Summary: The orthopedic device market is competitive, with several established players.
While the market is somewhat crowded, Onkos Surgical's focus on niche areas like musculoskeletal oncology and personalized solutions provides opportunities to differentiate and capture market share.
- Technical Challenge
-
Aspect: Moderate
Summary: Developing advanced orthopedic implants involves moderate technical challenges.
The development of specialized implants and technologies like NanoCept requires addressing moderate technical challenges, necessitating ongoing research and development efforts to ensure product efficacy and safety.
- Patent
-
Aspect: Strong
Summary: Onkos Surgical has secured patents for its innovative technologies.
Holding strong patents for technologies such as NanoCept provides Onkos Surgical with a competitive edge, protecting its innovations and supporting market exclusivity.
- Financing
-
Aspect: Well-funded
Summary: The company has secured significant funding from reputable investors.
With substantial investments from firms like 1315 Capital and Canaan Partners, Onkos Surgical is well-funded to advance its R&D pipeline, expand its commercial footprint, and enhance manufacturing capabilities.
- Regulatory
-
Aspect: 510k/PMA
Summary: Onkos Surgical has achieved FDA De Novo authorization for its NanoCept technology.
Obtaining FDA De Novo authorization for NanoCept demonstrates regulatory progress; however, ongoing compliance and approvals are critical for the successful commercialization of new products.
Opportunity Rollup
- Odds of Success
- 3.9
- Peak Market Share
- 5.6
- Segment CAGR
- 3.0%
- Market Segment
- Orthopedic Devices
- Market Sub Segment
- Musculoskeletal Oncology and Complex Orthopedic Procedures
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.28 |
| 2 | 0.84 |
| 3 | 1.96 |
| 4 | 3.92 |
| 5 | 5.60 |
Key Takeaway
Onkos Surgical is well-positioned in the orthopedic device market, leveraging innovative technologies and a strong team to address significant clinical needs, though it faces competition and regulatory challenges.